# Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.

Study · id `cardio:ct-nct06921616` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06921616](<https://clinicaltrials.gov/study/NCT06921616>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06921616

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 396 participants.

## Technical summary

Registry record NCT06921616. Randomized; triple masking; primary purpose treatment. Start 2025-05-01 (anticipated); primary completion 2026-11-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 396 participants (planned count; ClinicalTrials.gov record NCT06921616, source copy `cardio:ctgov-nct06921616-2025-04-13`, retrieved 2026-10-26)
- Planned start: 2025-05-01 (anticipated) (ClinicalTrials.gov record NCT06921616, source copy `cardio:ctgov-nct06921616-2025-04-13`, retrieved 2026-10-26)
- Primary completion: 2026-11-30 (anticipated) (ClinicalTrials.gov record NCT06921616, source copy `cardio:ctgov-nct06921616-2025-04-13`, retrieved 2026-10-26)
- Completion: 2027-01-31 (anticipated) (ClinicalTrials.gov record NCT06921616, source copy `cardio:ctgov-nct06921616-2025-04-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06921616, source copy `cardio:ctgov-nct06921616-2025-04-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06921616-2025-04-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.
- Acronym: HEMS
- Condition: Stroke
- Condition: Intracerebral Hemorrhage Lobar
- Condition: Methylprednisolone
- Condition: Surgery
- Intervention (Procedure): Simple neuroendoscopic hematoma evacuation
- Intervention (Combination product): Neuroendoscopic hematoma evacuation combined with sodium methylprednisolone succinate
- Lead sponsor: Yong Jiang
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: 6fc750e45ab47626ea16595aae4690593a1e3986ecd945020aacee5ebc60f9e3
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
